ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Core Viewpoint - ProQR Therapeutics has successfully closed a public offering of 18 million ordinary shares at a price of $3.50 per share, raising total gross proceeds of$63 million, and has also completed a private placement of 3,523,538 shares to Eli Lilly for approximately $12.3 million [1][2]. Group 1: Public Offering Details - The public offering consisted of 18,000,000 ordinary shares sold at a public offering price of$3.50 per share, resulting in gross proceeds of 63.0 million before expenses [1]. - The offering was managed by Evercore ISI, Cantor, Raymond James, and Oppenheimer & Co. as joint lead bookrunning managers [2]. Group 2: Private Placement Details - The private placement involved the sale of 3,523,538 ordinary shares to Eli Lilly at the same price as the public offering, totaling approximately 12.3 million in gross proceeds [2]. - Shares sold in the private placement were not subject to underwriting discounts or commissions [2]. Group 3: Regulatory Information - A shelf registration statement on Form F-3 for the offering was filed with the SEC on September 30, 2024, and was declared effective on October 10, 2024 [3]. - The offering was conducted only through a prospectus and prospectus supplement that are part of the registration statement [3]. Group 4: Company Overview - ProQR Therapeutics focuses on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology, which aims to create a new class of medicines for diseases with unmet needs [5].